Spots Global Cancer Trial Database for A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Official Title: A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Study ID: NCT05957367
Conditions
Study Description
Brief Summary: This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of DCC-3116 in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of DCC-3116 with other anticancer agents.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California, United States
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
START Midwest, Grand Rapids, Michigan, United States
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States
Memorial Sloan Kettering Cancer Center - Main Campus, New York, New York, United States
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Oregon Health & Science University, Portland, Oregon, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Contact Details
Name: Clinical Team
Affiliation: Deciphera Pharmaceuticals LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
